Thermo Fisher Scientific (TMO) is back in focus after Arcturus Therapeutics selected the company as its integrated manufacturing and clinical research partner for ARCT-032, an investigational mRNA therapy targeting cystic fibrosis.

Thermo Fisher Scientific’s recent collaboration announcements, index inclusion and upcoming second quarter results have arrived alongside a 30 day share price return of 8.58% and a 1 year total shareholder return of 22.36%. This suggests momentum has picked up after earlier year to date share price weakness.

If you are tracking how major healthcare contracts can reshape opportunity across the sector, this is a good moment to look at companies in a similar space using the 40 healthcare AI stocks

With Thermo Fisher Scientific shares rebounding, posting a 30 day return of 8.58% and trading at $523.44 compared with a published $596.26 price target and a similar intrinsic estimate, the key question is whether there is still an opportunity here or if the market is already pricing in future growth.

Most Popular Narrative: 14.4% Undervalued

On the latest narrative view, Thermo Fisher Scientific’s fair value of $611.56 sits well above the current $523.44 share price, putting the focus squarely on what has to go right in the underlying business.

Strong momentum in high-impact innovation evidenced by next-generation analytical tools like the Orbitrap mass spectrometers and AI integration into drug development workflows positions Thermo Fisher to capture incremental share as genomics and precision medicine proliferate, structurally boosting future revenues and margins.

Want to see what is behind that confidence in Thermo Fisher Scientific? The core of this narrative leans on steadier top line expansion, thicker margins and a richer profit multiple. Curious which specific revenue and earnings paths need to line up to reach that fair value estimate? The full narrative lays out the numbers behind that conviction.

Result: Fair Value of $611.56 (UNDERVALUED)

However, Thermo Fisher Scientific’s story can change quickly if academic and government funding remains weak or if China-related pressures continue to weigh on margins and demand.

Next Steps

With mixed sentiment around Thermo Fisher Scientific, and investors flagging both risks and rewards, this is a good time to review the data yourself and decide how it fits your own thesis. To see both sides set out clearly, start with the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Thermo Fisher Scientific?

Do not stop with Thermo Fisher Scientific. Broaden your watchlist now so you are not catching up later while others are already acting on fresh opportunities.

• Spot potential mispricing early and size up companies with quality metrics that still look overlooked using the screener containing 18 high quality undiscovered gems.
• Prioritise resilience and focus on businesses with financial strength by scanning the solid balance sheet and fundamentals stocks screener (46 results).
• Balance growth ambitions with capital protection and sift through companies that screen well on stability using the 75 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.